Literature DB >> 2897811

Relative analgesic potency of epidural fentanyl, alfentanil, and morphine in treatment of postoperative pain.

J Chrubasik1, H Wüst, J Schulte-Mönting, K Thon, M Zindler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897811     DOI: 10.1097/00000542-198806000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  8 in total

Review 1.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

2.  Equipotent dose regimens required when comparing epidural opioids.

Authors:  J Chrubasik; S Chrubasik; P Glass
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

3.  Bupivacaine 0.1% does not improve post-operative epidural fentanyl analgesia after abdominal or thoracic surgery.

Authors:  N H Badner; W E Komar
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

Review 4.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

6.  [Perioperative analgesia in adults : The concept of balanced analgesia.].

Authors:  J Jage
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

7.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

8.  A comparative study of patient-controlled epidural fentanyl and single dose epidural morphine for post-caesarean analgesia.

Authors:  P Y Yu; D R Gambling
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.